Quantum BioPharma signs Thermo Fisher contract for Phase 2 MS trial
Quantum said on Oct. 6 it had entered a Study Start-Up Agreement; it gave no first-dose or readout date.
Adrian Kessler
Preparations for a Phase 2 multiple sclerosis study gained a contractor as Quantum BioPharma Ltd. NASDAQQNTM FRA0K91 announced Tuesday that it had entered into a Study Start-Up Agreement with the clinical research business of Thermo Fisher Scientific Inc. NYSETMO. The step follows Quantum's Aug. 10 announcement that the U.S. Food and Drug Administration had cleared its investigational new drug application for a Lucid-MS trial.
In its Oct. 6 release, Quantum called the contract a Study Start-Up Agreement. Thermo Fisher's PPD clinical research business will support trial implementation, including start-up activities and related research services; the release gives no contract value or date for the first patient to receive the drug.
Toronto-based Quantum is a small-cap developer pursuing treatments for neurological and metabolic disorders through its subsidiaries. Lucid-MS, its lead investigational drug, is being developed for progressive forms of multiple sclerosis.
Quantum shares closed at US$3.27 on Nasdaq on Monday NASDAQQNTM, 4:00:01 p.m. EDT). That close preceded Tuesday's contract announcement, so it cannot establish a share reaction to the agreement.
Agreement Starts Formal Trial Work
Quantum's Aug. 10 announcement said site selection was already underway after the FDA allowed its investigational new drug application to proceed. The new contract identifies the clinical research business doing the start-up work, but the Oct. 6 release does not report that a patient has enrolled or been dosed.
The planned study is randomized, double-blind and placebo-controlled. Quantum says it will assess clinical and radiological measures relevant to disease progression, along with safety and tolerability. Its Oct. 6 release does not specify a participant count, named primary endpoint, dosing schedule or readout date, leaving the size and timing of the efficacy test open.
FDA clearance to begin the study is a regulatory permission, rather than evidence that Lucid-MS works in patients. Quantum describes the trial design in its releases, but neither release provides an FDA assessment of whether its chosen endpoints would support a future approval application.
Lucid-MS is designed to inhibit protein arginine deiminase 2, an enzyme Quantum links to myelin degradation. The company says preclinical models showed prevention and reversal of measures of myelin loss. Its Aug. 10 release also described a favourable safety profile in healthy Phase 1 participants, without reporting an efficacy result in people with multiple sclerosis.
"Our team brings deep experience in CNS and MS trials, along with an integrated approach that connects strategy and execution to help deliver these complex studies," Thermo Fisher vice-president and general manager for neuroscience clinical research Michael Cioffi said in the Oct. 6 release.
The contractor's role is operational: preparing and supporting the Phase 2 study. Quantum still owns the clinical question and the risk that patient outcomes may fail to support its proposed neuroprotective mechanism. Quantum's Oct. 6 release gives no payment amount, so the agreement cannot yet be translated into a cost per participant or a revised development budget.
Read more: Stoke Therapeutics details Dravet cognition analysis after FDA meeting
Cash Runway Rests On Earlier Spending
Quantum's Aug. 14 quarterly release reported US$3.65 million in cash and cash equivalents at June 30. Its combined cash, cash equivalents and digital assets were about US$9.5 million at that date. Management said those resources would fund planned operations to at least October 2027 if first-half spending patterns continued and the assets remained available.
The new contract adds an operational commitment without a disclosed price. The company's earlier runway estimate therefore provides a dated reference, but it does not show how much of the Phase 2 trial's work has been funded under this agreement or whether the study will finish before that projected runway ends.
Quantum's Oct. 6 release cited an estimate of about 2.8 million people living with multiple sclerosis worldwide. That is a figure for all forms of the disease, while this proposed study concerns progressive MS; the broad count cannot be treated as the trial's addressable population or an enrollment forecast.
Read more: Sernova and Seraxis close US$11.2M financing for diabetes trial
The next test of execution is an announced first patient dose. Quantum gave no dosing or readout date on Oct. 6, so that milestone will show when the start-up contract has moved beyond preparation and into patient treatment.
